In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as skin, lung, or bone and soft tissue cancer (sarcomas), they have not yet proven themselves as a treatment method.

Tumor shrinkage was achieved only in rare cases, but the side effects were all the more severe. An international research group led by scientists from the National Center for Tumor Diseases (NCT/UCC) in Dresden has now conducted a Phase I clinical trial of a novel cell therapy approach that also shows promise for solid tumors.

The results are published in Nature Medicine.